Septerna Inc
SEPN29.580USD
+2.040+7.41%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
1.32BMarket Cap
2.15P/E TTM
More Details of Septerna Inc Company
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Septerna Inc Info
Ticker SymbolSEPN
Company nameSepterna Inc
IPO dateOct 25, 2024
CEOFiner (Jeffrey)
Number of employees75
Security typeOrdinary Share
Fiscal year-endOct 25
Address250 East Grand Avenue, Suite 65
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16503383533
Websitehttps://septerna.com/
Ticker SymbolSEPN
IPO dateOct 25, 2024
CEOFiner (Jeffrey)
Company Executives of Septerna Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
826.91K
-12.75%
Dr. Uwe Klein, Ph.D.
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
135.66K
+20.42%
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Director
117.42K
-22.44%
Mr. Daniel (Dan) Long
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
97.54K
-3.46%
Ms. Samira Shaikhly
Ms. Samira Shaikhly
Chief People Officer
Chief People Officer
36.81K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Abraham (Abe) Bassan
Mr. Abraham (Abe) Bassan
Independent Director
Independent Director
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
--
-100.00%
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
Ms. Elizabeth P. (Liz) Bhatt
Ms. Elizabeth P. (Liz) Bhatt
President
President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
826.91K
-12.75%
Dr. Uwe Klein, Ph.D.
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
135.66K
+20.42%
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Director
117.42K
-22.44%
Mr. Daniel (Dan) Long
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
97.54K
-3.46%
Ms. Samira Shaikhly
Ms. Samira Shaikhly
Chief People Officer
Chief People Officer
36.81K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
23.29%
RA Capital Management, LP
15.62%
Driehaus Capital Management, LLC
10.99%
BVF Partners L.P.
8.97%
Samsara BioCapital, LLC
7.03%
Other
34.10%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
23.29%
RA Capital Management, LP
15.62%
Driehaus Capital Management, LLC
10.99%
BVF Partners L.P.
8.97%
Samsara BioCapital, LLC
7.03%
Other
34.10%
Shareholder Types
Shareholders
Proportion
Venture Capital
48.15%
Investment Advisor/Hedge Fund
18.11%
Hedge Fund
15.54%
Investment Advisor
14.33%
Research Firm
3.37%
Individual Investor
3.15%
Private Equity
1.21%
Bank and Trust
0.06%
Insurance Company
0.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
157
44.91M
100.74%
-6.96M
2025Q2
140
48.42M
108.66%
+736.53K
2025Q1
139
54.98M
123.75%
+8.24M
2024Q4
107
54.00M
121.73%
+28.70M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
10.43M
23.39%
--
--
Jun 30, 2025
RA Capital Management, LP
7.00M
15.69%
--
--
Jun 30, 2025
Driehaus Capital Management, LLC
4.68M
10.5%
+20.52K
+0.44%
Jun 30, 2025
BVF Partners L.P.
4.40M
9.86%
--
--
Jun 30, 2025
Samsara BioCapital, LLC
3.15M
7.06%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
2.20M
4.94%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.41M
3.17%
+419.32K
+42.14%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.42M
3.18%
-33.09K
-2.28%
Jun 30, 2025
Avoro Capital Advisors LLC
1.24M
2.78%
-100.00K
-7.48%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.25M
2.81%
+90.92K
+7.82%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust Multi-Manager Small Cap Opportunities ETF
0.62%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
iShares Russell 2000 Value ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Global X Russell 2000 ETF
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.01%
View more
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.62%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.49%
iShares Russell 2000 Value ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Septerna Inc?
The top five shareholders of Septerna Inc are:
Third Rock Ventures, LLC holds 10.43M shares, accounting for 23.39% of the total shares.
RA Capital Management, LP holds 7.00M shares, accounting for 15.69% of the total shares.
Driehaus Capital Management, LLC holds 4.68M shares, accounting for 10.50% of the total shares.
BVF Partners L.P. holds 4.40M shares, accounting for 9.86% of the total shares.
Samsara BioCapital, LLC holds 3.15M shares, accounting for 7.06% of the total shares.
Third Rock Ventures, LLC holds 10.43M shares, accounting for 23.39% of the total shares.
RA Capital Management, LP holds 7.00M shares, accounting for 15.69% of the total shares.
Driehaus Capital Management, LLC holds 4.68M shares, accounting for 10.50% of the total shares.
BVF Partners L.P. holds 4.40M shares, accounting for 9.86% of the total shares.
Samsara BioCapital, LLC holds 3.15M shares, accounting for 7.06% of the total shares.
What are the top three shareholder types of Septerna Inc?
The top three shareholder types of Septerna Inc are:
Third Rock Ventures, LLC
RA Capital Management, LP
Driehaus Capital Management, LLC
Third Rock Ventures, LLC
RA Capital Management, LP
Driehaus Capital Management, LLC
How many institutions hold shares of Septerna Inc (SEPN)?
As of 2025Q3, 157 institutions hold shares of Septerna Inc, with a combined market value of approximately 44.91M, accounting for 100.74% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.92%.
What is the biggest source of revenue for Septerna Inc?
In --, the -- business generated the highest revenue for Septerna Inc, amounting to -- and accounting for --% of total revenue.
